Objective: To compare the occurrence of systemic infection or death in preterm infants with elective percutaneous central line (PCVL) placement versus peripheral intravenous catheter (PIV) placement.
Introduction
The incidence of preterm birth continues to increase despite enhancements in obstetrical care, including the treatment of preterm labor. The need for intravenous (IV) access, essential for the provision of fluids, nutrition and medications in these neonates, is frequently problematic. Despite the trend toward early feedings, many of these infants require long-term IV therapy. Repeated attempts to obtain peripheral IV access disrupt the skin's integrity, breaching the first line of defense against systemic infection. The optimal method of delivering fluids, medications and nutrition intravenously has not yet been determined.
Preterm infants are at a high risk of developing systemic infection because of their immature immune systems. In the 12 National Institute of Child Health and Human Development (NICHD) neonatal research network centers in 1998 to 2000, 21% of 6215 very low birth weight infants who survived beyond 3 days had one or more episodes of blood cultureproven systemic infection. Late-onset systemic infection was associated with prolonged hospitalization and increased incidence of death. 1 There have been only two published randomized trials that compared the benefits and the risks of percutaneous central lines (PCVLs) versus peripheral intravenous catheters (PIVs) in the high-risk preterm neonatal population. Janes et al. 2 conducted a randomized trial in 63 infants to compare the occurrence of sepsis and insertion attempts between PCVLs and PIVs in infants <1251 g who required parenteral fluids. They found no significant difference in the occurrence of proven sepsis (PCVL group 42% and PIV group 48%), antibiotic courses or duration of IV fluids. The number of insertion attempts was significantly lower in the PCVL group. Ainsworth et al. 3 conducted a randomized trial of 49 infants and compared the occurrence of sepsis in neonates who received parenteral nutrition via PCVLs versus PIVs. They found no difference in the occurrence of systemic infection between the two groups (PCVL group 46% and PIV group 40%). There was a significant difference in the parenteral nutrition received; the PIV group received less because of lack of venous access. This finding prompted early termination of the study. In a Cochrane review that summarized the findings of these trials along with a third unpublished trial by Annibale et al., 4 the authors concluded that 'More trials are needed to determine whether delivering intravenous nutrition into superficial or to deep veins is better for newborn infants'. 5 This randomized clinical trial was designed to address the following research question: among infants p1250 g birth weight or p30 weeks gestation, does early elective placement of a PCVL, as compared to use of PIVs with PCVL placement only when peripheral access is no longer feasible, change the occurrence of late-onset systemic infection (positive blood or cerebrospinal fluid (CSF) culture treated with >5 days antibiotics) or death?
Methods

Study population
The setting for the study was an 80-bed neonatal intensive care unit (NICU), located in the Memorial Hermann Children's Hospital. Eligibility criteria included (1) birth weight p1250 g or gestational age p30 weeks at birth, (2) appropriate for gestational age, (3) admitted or transferred to the NICU at p96 hrs of age and, (5) expected to require IV therapy for at least 5 more days. The exclusion criteria were (1) contraindications to placement of a PCVL (coagulopathies or documented venous thrombus), (2) the presence of a central venous catheter (other than an umbilical venous catheter) or (3) congenital anomalies that disrupt skin integrity. The predetermined sample size of 100 (50 per group) was based on the largest sample that could be feasibly enrolled in a 12-to 18-month period in this NICU. We estimated that this sample size would allow us to detect a reduction in death or systemic infection from 50 to 23% with 80% power (two-sided a ¼ 0.05).
Human subjects protection
The study was approved by the Committee for the Protection of Human Subjects of the University of Texas Health Science Center at Houston and by Memorial Hermann Healthcare System. A study investigator or the attending neonatologist sought informed consent for the study; consent was obtained from at least one parent for all subjects before enrollment.
Recruitment and randomization procedures
Infants were screened for eligibility in the first 72 h of life. If eligibility criteria were met and consent was obtained, infants could be randomized until 96 h of life. Randomization was accomplished using sequentially numbered opaque sealed envelopes, with a computer-generated random number sequence designed to achieve balance after 100 infants were enrolled. Infants were enrolled from October 2000 to January 2002.
Study interventions
Once the infant was randomized, a PCVL was placed as soon as feasible for infants in the PCVL group; in the PIV group, PIV access was maintained. If a UVC was in place, the PCVL was placed after the attending physician decided to remove the UVC. Using sterile technique, one of a small group of specially trained neonatal nurses placed the PCVLs. Vygon 2 French catheters with nonbreakaway introducer needles were used. All but two of the PCVLs were placed in the head, neck or upper limbs; placement of these lines was confirmed at T4 to T6 by radiography. Two lines were placed in the saphenous vein. Placement of these lines was confirmed to be above the femoral area and below the entrance to the right atrium (BT6). The same specially trained nurses were responsible for changing the PCVL dressings and performing any necessary line manipulations. When changing tubing or entering the line for medication administration, staff nurses used sterile technique with hat, mask, sterile gown, and gloves. Three betadine swabs, with at least 1 min drying time for each, were used when placing the PCVLs, changing fluids or entering the line for any reason. No prophylactic antibiotics were used. NICU staff nurses, using clean technique, placed the PIVs. As allowed by compatibility, medications were delivered via the PCVL using sterile technique. In the PCVL group, PIVs were used as needed for blood products and incompatible medications. The tubing for the PCVLs was changed using sterile technique, whereas the tubing for the PIVs was changed using clean technique, as was routine practice in the NICU. The PCVLs were monitored daily to ensure that the PCVL dressing was occlusive; when necessary, the dressing was changed. Any PCVL that was leaking or occluded was repaired or removed, and the need for another PCVL was discussed with the infant's physician.
Any infant in the PIV group who required placement of a PCVL owing to inability to maintain IV access via PIV received a PCVL (using the techniques described above for the PCVL group) and remained in the assigned PIV group for analysis. If a PCVL could not be placed in an infant assigned to the PCVL group, the infant's IV access was maintained with PIVs. Feedings were advanced according to a unit feeding protocol; IV fluids were decreased and discontinued at the discretion of the attending physician. When IV fluids were discontinued, some lines were kept in place for 2 to 3 days if the infant had a complicated feeding course but most were removed within 24 h of discontinuing IV fluids.
Outcome determinations
The primary outcome for the study was the proportion of infants who had at least one episode of systemic infection or died between randomization and the study end point (when the infant had not required IV support for 7 consecutive days). For this study, systemic infection was defined as a positive blood or CSF culture (for bacteria or fungus) that was treated for at least 5 days with antibiotics or antifungals. We used the methodology of Stoll et al., 1 (5 days of treatment) to discriminate, based on the clinicians' assessment, true systemic infection from a contaminated blood culture. When an infant displayed signs/symptoms of infection, a systemic infection workup was performed as routinely ordered by the infant's physician. At a minimum, the systemic infection workup included a complete blood count and a blood culture drawn from a peripheral site. Routine unit practice was to draw 1 ml of blood for blood cultures. Antibiotic therapy was started and discontinued as deemed appropriate by the infant's physician. We included death in our composite outcome because death competes with systemic infection in that infants who die soon after randomization are not at risk for infection.
When a systemic infection evaluation was performed, the PCVL remained in place if the culture results were negative at 48 h, or if the culture results were positive and the infant's clinical condition was improving. The latter was reported as systemic infection and the systemic infection was treated with the PCVL in place. Repeat blood cultures were drawn at the discretion of the physician. If repeat blood culture(s) were positive, the PCVL was discontinued and IV therapy was continued with a PIV. If the infant completed the course of antibiotics and again displayed symptoms of systemic infection with a positive blood or CSF culture, this was reported as a second episode of systemic infection.
Predefined secondary outcomes included number of systemic infection episodes per infant, episodes of systemic infection per 100 study days, deaths before discharge, length of hospital stay, catheter complications and number of skin punctures for IV access. The staff nurses recorded the number of skin punctures on the study data sheet. Systemic infection and number of skin punctures were monitored until the infants did not require IV support for 7 consecutive days. 'Study days' were counted from the date of randomization until the end of this 7-day interval. Length of hospital stay and death were monitored until hospital discharge. For comparing length of stay, it would be misleading to assign a relatively short duration of stay (a good outcome) to an infant who died. We therefore expressed this outcome as the number of days alive after discharge in the first 730 days (2 years) after birth.
Statistical analysis
Categorical outcomes were compared using relative risk (RR) and 95% confidence intervals (CIs). Continuous outcomes were compared with a nonparametric test for asymmetrically distributed data. Data were analyzed using NCSS 2004 (Kaysville, UT, USA). Infants were analyzed according to their assigned treatment group, regardless of whether they received the alternative treatment (intention-to-treat principle).
Results
Fifty subjects were randomized to each group. Consent was withdrawn for one infant in the PCVL group. Three additional infants in the PCVL group were excluded from the primary analysis of all enrolled infants because it was determined (after randomization) that their birth weight and gestational age exceeded the eligibility limits for the study. The remaining 96 patients were included in the primary analysis of all enrolled infants. A secondary analysis was performed on all randomized infants (excluding only the infant who was withdrawn from the study). Baseline characteristics are summarized in Table 1 . The groups were comparable with respect to birth weight, gestational age, gender, race and place of birth (inborn versus outborn).
Study outcomes are presented in Table 2 . There were no statistically significant differences in systemic infection or death (combined outcome), systemic infection, death (analyzed separately) or length of stay between the groups in the analyses of all enrolled infants. In the PCVL group, two infants died at 14 and 23 days of age; in the PIV group, three infants died at 12, 17 and 20 days of age. All of these deaths occurred during the 'study days'; so all were included in the 'systemic infection or death' combined outcome. Additional information about the types of infection is presented in Table 3 .
In the secondary analyses of all randomized infants, there were no significant differences in any of these outcomes; the outcome of systemic infection or death occurred in 17/49 infants in the PCVL group and 14/50 infants in the PIV group (RR ¼ 1.24, 95% CI 0.65, 2.39; risk difference (RD) ¼ 0.07, 95% CI À0.11, 0.25); the outcome of systemic infection occurred in 15/49 infants in the PCVL group and 13/50 infants in the PIV group (RR ¼ 1.18, 95% CI 0.59, 2.38; RD ¼ 0.05, 95% CI À0.13, 0.22).
In the PIV group, 10 infants received a PCVL because of difficulty maintaining IV access with PIVs; in the PCVL group, 2/46 infants did not receive a PCVL. Central lines were surgically placed if prolonged access could not be maintained with PIVs or PCVLs; 
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one infant in the PCVL group and two infants in the PIV group had central lines surgically placed. The number of skin punctures for IV access (in Table 2 ) was significantly different between the study groups. These differences persisted when all randomized infants were analyzed (P ¼ 0.02 for skin punctures per infant, P<0.01 for skin punctures per study day). The most common problems associated with both types of catheter included infiltration (two in the PCVL group and 278 in the PIV group) and leaking or clotted catheters (10 in the PCVL group and 196 in the PIV group). Malfunctioning catheters were removed without difficulty. There were no other serious complications or deaths attributed to either PIVs or PCVLs. There were five extravasations with skin breakdown that were treated with hyaluronidase in the PIV group. One PCVL was accidentally placed in an artery and was removed upon discovery with no permanent complications noted.
Discussion
The results from this study are consistent with the results from the previous randomized trials by Janes et al. 2 and Ainsworth et al. 3 There have now been three randomized trials reporting no increase in systemic infection with the use of PCVLs and two of these trials have reported a decrease in the frequency of skin punctures with the use of PCVLs. In 2004, a review of the findings in these previously published trials and one other unpublished trial were combined and published in The Cochrane Library. 5 This review reported no increase in the risk of infection and fewer catheter placements when PCVL lines were used. In this review, the point estimates for the RR of systemic infection were 1.15 and 0.81 for the two individual studies that reported this outcome, but the CI for the summary estimate was wide (RR ¼ 0.90; 95% CI 0.62, 1.32). The combined sample size in this review was 262 preterm infants with an average gestational age from 26 to 29 weeks. By including this study in an updated review, the summary estimates of the risks and benefits of PCVLs as compared to peripheral IV line will be more precise with the addition of 100 more subjects. 6 Several studies have shown a decrease in the rate of infection when personnel are trained in the care of PCVLs and a protocol is in place for the care of these lines. [7] [8] [9] At Hermann Children's Hospital, a limited group of specially trained nurses placed and maintained the PCVLs. Because various technical aspects of their insertion and care likely influence catheter-associated infections, the findings from this study may not be generalizable to settings where central line care protocols are less strictly enforced.
The most striking benefit of PCVLs in preterm infants is the decrease in the frequency of skin punctures when these lines are used in lieu of PIVs. PIVs also carry the risk of IV infiltrates (some requiring plastic surgery), placement in an artery and blood clots. In addition to the obvious short-term effects of frequent skin punctures, long-term effects of frequent painful stimuli have been reported in follow-up studies of preterm infants. 10, 11 These risks of PIVs must be weighed against the risks associated with PCVLs. Apart from infection, the use of PCVLs can cause other complications, some of which may be serious or even fatal. Other complications include infiltration, blood clots, inability to remove catheter, placement in an artery and pericardial effusion. Most of the severe permanent complications are infrequent (we observed none in our 46 patients) and some (e.g. pericardial effusion) are very rare, but they do occur. In an article by Pettit, 12 the complications of PCVLs were summarized using data from the reports in the literature. The reported incidences of infections were 0 to 25%, occlusion 2.2 to 33.6%, dislodgment 2 to 11.6%, leakage 1.7 to 10%, phlebitis 0 to 6.9%, breakage 0 to 5.9%, malposition 1 to 5.3%, pleural effusion 0 to 1.4%, migration 1%, retention <1%, thrombosis 0 to 1% and pericardial effusion 0 to 0.7%. Beardsall et al. 13 have estimated the risk of pericardial effusion/cardiac tamponade to be 1.8/1000 lines with an estimated fatality rate of 0.7 per 1000 lines. Cartwright 14 reported a 5.3% risk of septicemia and a 0.05% risk of nonfatal pericardial effusion in 2186 central catheters placed in neonates. Proper placement and sterile care of the lines will reduce most of the risk, but cannot prevent them.
This randomized controlled trial shows that PCVLs decrease the frequency of painful skin punctures without significantly increasing the occurrence of systemic infection or the length of stay. With the relatively small sample size in our study, we could not exclude a clinically important difference in systemic infection. Our data are consistent with the findings in other randomized trials. 5 When all these trials are considered, there is no consistent effect of PCVLs versus PIVs on systemic infection. Future research in this area will be needed to determine whether there is a small increase or decrease in the risk of infection with PCVLs and to quantify all the less common risks of PCVLs. Large trials or a systematic review of high-quality smaller trials will be needed to quantify these relatively rare events so that clinicians and parents can carefully weigh the advantages and disadvantages of PCVL use and make value judgments about whether the decrease in skin punctures observed with elective placement of PCVLs justifies the risk of adverse outcomes.
